High‐dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia

Bruce A Peterson, Clara D. Bloomfield

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Six adults with refractory acute lymphocytic leukemia (ALL) were treated with high‐dose methotrexate, citrovorum factor, and vincristine. All patients had previously received extensive treatment with standard therapeutic agents, including vincristine, and all but one had received prior methotrexate. Two patients achieved complete remission and one achieved partial remission. Responses were seen at 3–6 gm/m2 of methotrexate. The durations of remission were 7–10 weeks. High‐dose methotrexate with citrovorum factor is effective in the treatment of advanced ALL and should be considered for inclusion in initial combination chemotherapeutic regimens for adult ALL.

Original languageEnglish (US)
Pages (from-to)79-84
Number of pages6
JournalMedical and Pediatric Oncology
Volume5
Issue number1
DOIs
StatePublished - 1978

Keywords

  • acute lymphocytic leukemia
  • chemotherapy
  • high‐dose methotrexate

Fingerprint Dive into the research topics of 'High‐dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this